|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash used in operating activities: | |||||
| Amortization (accretion) of investments | |||||
| Other-than-temporary impairments | |||||
| Realized investment gains, net | |||||
| Change in fair value of equity securities | |||||
| Unrealized trading losses included in income | |||||
| Realized trading losses included in income | |||||
| Change in allowance from credit losses | |||||
| Amortization of cost of insurance acquired | |||||
| Provision for deferred income taxes | |||||
| Depreciation and depletion | |||||
| Stock-based compensation | |||||
| Charges for mortality and administration of universal life and annuity products | |||||
| Interest credited to account balances | |||||
| Change in accrued investment income | |||||
| Change in reinsurance receivables | |||||
| Change in policy liabilities and accruals | |||||
| Change in income taxes receivable | |||||
| Change in other assets and liabilities, net | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Proceeds from investments sold and matured: | |||||
| Fixed maturities available for sale | |||||
| Equity securities | |||||
| Trading securities | |||||
| Mortgage loans | |||||
| Real estate | |||||
| Notes receivable | |||||
| Policy loans | |||||
| Short-term investments | |||||
| Total proceeds from investments sold and matured | |||||
| Cost of investments acquired: | |||||
| Fixed maturities available for sale | |||||
| Equity securities | |||||
| Trading securities | |||||
| Mortgage loans | |||||
| Real estate | |||||
| Notes receivable | |||||
| Policy loans | |||||
| Short-term investments | |||||
| Total cost of investments acquired | |||||
| Net cash provided by investing activities | |||||
| Cash flows from financing activities: | |||||
| Policyholder contract deposits | |||||
| Policyholder contract withdrawals | |||||
| Proceeds from notes payable/line of credit | |||||
| Payments of principal on notes payable/line of credit | |||||
| Purchase of treasury stock | |||||
| Noncontrolling (distributions) of consolidated subsidiary | |||||
| Net cash used in financing activities | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of period | |||||
| Cash and cash equivalents at end of period | |||||
Loading...
